The LOGIC-1 clinical research study, sponsored by Peptilogics Inc., is for people who develop a prosthetic joint infection (PJI) after their knee replacement (also known as arthroplasty). The study will test a new investigational medication to learn if it can help breakdown biofilm and kill the bacteria that cause PJI.
The study medication is given during a standard procedure called a Debridement Antibiotics and Implant Retention (DAIR) procedure. All study participants receive the study medication, and there is no cost to participate in the study.
Study participants may be able to join the study if they meet the following requirements:
Participation in the LOGIC-1 study lasts 1 year. Study participants can expect the following:
Review & Sign the Informed Consent Form
Receive study health assessments to confirm if you qualify for the study. This is called screening.
Receive the study medication during a standard-of-care (usual treatment) procedure called a DAIR (Debridement Antibiotics and Implant Retention) procedure.
Stay at the hospital for a few days following the DAIR procedure. Study participants do not stay longer than what is normally required after a DAIR procedure.
In addition to the study medication, study participants will be prescribed the same (standard of care) antibiotic medication you would receive intravenously (IV) or by mouth if you were not in the study.
The option of tracking daily steps using a smartwatch for 1 year.
Willing and able to be followed for 12 months after the DAIR procedure. One visit may be through telehealth. Schedule additional study visits if symptoms worsen.
Participation in a clinical study is voluntary. You may ask any questions or leave the study at any time, for any reason.
